Zacks Rating on Merck & Company (MRK)

Merck & Company (MRK) : The consensus on Merck & Company (MRK) based on 13 analyst recommendation on the company stock is 2.08, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 6 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 7 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Merck & Company (MRK) has been rated by 11 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $80 and the lowest price target forecast is $57. The average forecast of all the analysts is $64.73 and the expected standard deviation is $7.52.


Shares of Merck & Co., Inc. rose by 0.86% in the last five trading days and 8.57% for the last 4 weeks. Merck & Co., Inc. is up 15.29% in the last 3-month period. Year-to-Date the stock performance stands at 22.42%. Merck & Company (NYSE:MRK): stock turned positive on Tuesday. Though the stock opened at $63.71, the bulls momentum made the stock top out at $63.88 level for the day. The stock recorded a low of $63.37 and closed the trading day at $63.58, in the green by 0.05%. The total traded volume for the day was 5,798,353. The stock had closed at $63.55 in the previous days trading.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.